Oncology & Hematology

This cohort study estimates age-specific cancer incidence rates among people with HIV in the US using a large sample from population-based data registries.

This Editorial discusses the urgent need to better understand the effectiveness of noninvasive stool-based tests such as the fecal immunochemical test and fecal occult blood test in younger populations with colorectal cancer.

This cohort study evaluates whether initiating fecal immunochemical test screening at age 40 to 49 years, rather than at the currently recommended age of 50 years, reduces colorectal cancer incidence and mortality.

This randomized clinical trial evaluates preoperative stereotactic radiation therapy logistics and safety profile compared with postoperative stereotactic radiation therapy in patients with brain metastases.

This Viewpoint discusses the need to optimize screening strategies for prostate cancer, including more widespread use of magnetic resonance imaging (MRI)–targeted screening, to overcome limitations of prostate-specific antigen testing.

This cohort study evaluates the associations between time-varying body mass index/physical activity and subsequent neoplasm risk among childhood cancer survivors.

The prospective ACHIEVE study by Li et al explores selective dose intensification for patients with EGFR-variant non–small cell lung cancer (NSCLC). In addition to demonstrating safety and efficacy with this approach, the study draws attention to the strategy behind dose selection in the era of targeted therapy and may support revisiting long-held practices.

This Viewpoint reports on the recent advances in treatment for small cell lung cancer (SCLC), including the use of personalized therapies for this aggressive cancer and its numerous subtypes.

A 50-year-old woman presented to the dermatology department with a 10-year history of recurrent plaque outbreaks between her toes and a history of Bowen disease in the anus that had been treated with excision and skin grafting. What is your diagnosis?

This nonrandomized clinical trial including female patients in China investigates the use of utidelone plus bevacizumab as a potential therapy for patients with ERBB2-negative metastatic breast cancer (MBC) and active brain metastases.

This nonrandomized clinical trial evaluates the activity and safety of high-dose aumolertinib in patients with untreated EGFR-variant non–small cell lung cancer and brain metastases.

In Reply We carefully read the letter from Sertesam Camoz et al. We appreciate the opportunity to clarify the points that were raised; most of them were already discussed in our original work.

To the Editor We read the article by Dieci et al with great interest considering the cohort size, phase 3 data, and 9-year follow-up of the study. The article is also valuable for the reported overall survival (OS) data regarding the prognostic value of tumor-infiltrating lymphocytes (TILs).

This cohort study examines the use of human epidermal growth factor receptor 2 immunohistochemistry pan-tumor testing among patients with solid tumors.

This Viewpoint presents considerations and potential patient scenarios to help guide clinicians in optimizing care for patients with cancer who are fasting during Ramadan.

This randomized clinical trial compares the efficacy and safety of induction-concurrent with concurrent-adjuvant chemotherapy in high-risk N2 to N3 nasopharyngeal carcinoma.

This study evaluates long-term survival outcomes for patients with newly diagnosed multiple myeloma treated with earlier total therapy protocols

This prespecified secondary analysis of a randomized clinical trial assesses the role of circulating tumor DNA in predicting progression-free and overall survival in patients with deficient mismatch repair/microsatellite instability−high metastatic colorectal cancer treated with immune checkpoint inhibitors.

This Viewpoint discusses the use of buprenorphine to treat cancer pain and difficulties in affordability and access despite its efficacy and safety compared with full-agonist opioids.

JAMA Oncology is committed to publishing influential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with cancer.